Compared to CAR T cell therapies, which are limited to surface antigens, TCR T cell therapies offer the advantage of targeting intracellular antigens presented by MHC molecules, broadening their applicability across cancer types, especially solid tumors (6, 15). This evidence concerns the gene HLA-C and cancer.